. Author manuscript; available in PMC: 2010 Aug 19.

Published in final edited form as: Endocrinology. 2003 Sep;144(9):3950–3957. doi: 10.1210/en.2002-0123

TABLE 1.

Total body BMD, BMC, bone area, percentage of fat, and lean body mass measured by DEXA

Parameters	Group	End of treatment	After withdrawal (1)	After withdrawal (2)
BMD (mg/cm²)	1	25.5 ± 0.5	27.9 ± 0.4	28.4 ± 0.4
	2	29.9 ± 0.6^a	32.5 ± 0.5^a,^c	33.6 ± 0.7^a,^c
	3	26.8 ± 0.4	28.7 ± 0.3	29.3 ± 0.4
	4	29.1 ± 0.6^a	32.1 ± 0.9^a,^b	32.0 ± 1.3^a
	5	28.4 ± 0.4	29.3 ± 0.4	N.A.
	6	32.7 ± 0.4^a	35.5 ± 0.8^a,^b	N.A.
	7	33.7 ± 0.8	31.7 ± 0.5	N.A.
	8	36.3 ± 0.4^a	36.1 ± 0.5^a	N.A.
BMC (mg)	1	75.6 ± 3.9	99.6 ± 4.3	116.0 ± 6.2
	2	143.6 ± 6.3^a	166.6 ± 5.3^a,^c	191.6 ± 9.9^a,^c,^d
	3	90.3 ± 5.2	116.2 ± 3.2	121.2 ± 7.9
	4	143.5 ± 8.5^a	176.8 ± 10.7^a,^b	172.9 ± 17.1^a
	5	110.5 ± 3.6	123.5 ± 4.4	N.A.
	6	192.0 ± 4.6^a	214.6 ± 11.2^a	N.A.
	7	162.8 ± 9.4	149.3 ± 6.5	N.A.
	8	239.6 ± 6.7^a	238.6 ± 6.6^a	N.A.
Bone area (cm²)	1	2.96 ± 0.10	3.57 ± 0.11	4.07 ± 0.17
	2	4.80 ± 0.14^a	5.12 ± 0.10^a	5.68 ± 0.19^a,^c,^d
	3	3.36 ± 0.15	4.05 ± 0.10	4.11 ± 0.21
	4	4.90 ± 0.21^a	5.47 ± 0.20^a	5.34 ± 0.29^a
	5	3.88 ± 0.09	4.20 ± 0.11	N.A.
	6	5.87 ± 0.07^a	6.03 ± 0.21^a	N.A.
	7	4.82 ± 0.19	4.70 ± 0.14	N.A.
	8	6.59 ± 0.12^a	6.60 ± 0.13^a	N.A.
Lean body mass (g)	1	6.25 ± 0.23	8.13 ± 0.33	8.48 ± 0.40
	2	11.24 ± 0.45^a	10.79 ± 0.43^a	9.89 ± 0.49^a,^b
	3	5.69 ± 0.17	7.84 ± 0.19	8.04 ± 0.46
	4	10.56 ± 0.36^a	9.64 ± 0.35^a	9.07 ± 0.32^c
	5	7.63 ± 0.26	8.13 ± 0.28	N.A.
	6	13.31 ± 0.44^a	11.39 ± 0.53^a,^c	N.A.
	7	9.84 ± 0.25	10.30 ± 0.38	N.A.
	8	15.02 ± 0.24^a	12.32 ± 0.18^a,^c	N.A.
% Body fat (%)	1	16.56 ± 0.28	22.05 ± 1.76	27.85 ± 2.37
	2	12.13 ± 0.29^a	19.76 ± 1.09^c	27.90 ± 2.56^c,^e
	3	14.67 ± 0.74	15.16 ± 1.44	26.54 ± 1.25
	4	9.49 ± 0.29^a	10.21 ± 0.49^a	23.45 ± 1.71^c,^e
	5	21.27 ± 1.54	25.58 ± 1.59	N.A.
	6	12.02 ± 0.58^a	26.75 ± 0.94^c	N.A.
	7	33.18 ± 1.44	33.23 ± 0.76	N.A.
	8	14.62 ± 0.94^a	25.18 ± 1.18^a,^c	N.A.

The values are mean ± SEM (n = 5–8 per group). 1, Represents 3 wk (for groups 1–4, 7 and 8) or 4 wk (for groups 5 and 6) after withdrawal of GH treatment. 2, Represents 7 wk after withdrawal of GH treatment. N.A., Not applicable.

P < 0.05 vs. corresponding control group by t test or post hoc test.

P < 0.05 and

represents P < 0.01 vs. corresponding GH treatment at end of treatment by one-way ANOVA and post hoc test.

represents P < 0.05 and

represents P < 0.01 vs. corresponding GH treatment at after withdrawal (1) of GH treatment by one-way ANOVA and post hoc test.